News

Donanemab was approved by the FDA in July 2024 to treat adults with early symptomatic Alzheimer's disease with confirmed ...
A labeling mistake has led to a nationwide recall of four different types of Ritz peanut butter cracker sandwich cartons, ...
The US Food and Drug Administration is revising the labeling of all extended-release attention-deficit/hyperactivity disorder (ADHD) medications.
The FDA will allow a new dosing schedule for Eli Lilly’s Alzheimer’s drug Kisunla that could lessen a known side effect of ...
FDA Commissioner Dr. Marty Makary says the agency will revisit the labeling system for OxyContin and similar drugs, saying ...
Mondelēz Global LLC, the company that owns the Ritz brand, stated the recall involves four carton sizes of its Ritz peanut ...
If you've recently purchased these, make sure to check the labels. The company said some sandwiches may be labeled as cheese, ...
Four carton sizes were recalled due to individually wrapped packs that may be incorrectly labeled as "cheese" even though ...
Syndax now has two approved therapies, but the share price remains under pressure despite these milestones. See why SNDX ...
The manufacturer of RITZ cracker sandwiches has announced an urgent recall due to a labeling error that the U.S. Food and Drug Administration said could cause a serious or life-threatening ...
Ritz accidentally mislabeled peanut butter crackers as cheese crackers. After realizing the recent error, Mondelez ...
The FDA has approved a label update for Eli Lilly’s Kisunla, an Alzheimer’s treatment, by modifying the recommended dosing schedule for adults with early symptomatic Alzheimer’s disease. The update ...